|
CHRISTIAN ROHLFF, PHD
CHIEF EXECUTIVE OFFICER Dr Rohlff became Chief Executive of Oxford BioTherapeutics in 2004, after founding the company and acquiring key targeting technology, bioinformatics data and intellectual property. He brings more than 20 years of experience in the international biotechnology industry to OBT. Following his PhD in Pharmacology from Georgetown University, he held a number of positions at the US National Cancer Institute. Prior to joining OBT, he held a number of positions of increasing seniority with Oxford Glycosciences, and led the company’s partnerships in oncology with Pfizer, GSK, Bayer, Wyeth, Takeda, Oxford University and the FDA. |
|
ABDERRAHIM FANDI, MD, PHD
CHIEF MEDICAL OFFICER Dr Fandi is a docteur of Medecine and Medical Oncology at Paris University Rene Descart, Paris, France. Following his training in medical oncology, a Clinial Pharmacology Oncology degree from Paris VII Lariboisiere Saint-Louis, a PhD in Experimental Paediatrics at the University of Turin and three years in academia at the Phase I Program Unit at Institut Gustave Roussy, he joined the pharmaceutical industry in 1995 working for major companies including Sanofi, AstraZeneca, Bristol Myers Squibb and Novartis. More recently, he spent the past seven years at Celegene first as site head of the New Jersey site leading a large multidisciplinary clinical development team before moving to the European site in Switzerland in 2014 where he led Celgene's epigenetic program in combination with immune-oncology checkpoints in solid tumours. Dr Fandi brings a wealth of experience in Clinical Reseach and Development, and health authority interactions (including the FDA), to OBT, having led the development of several novel chemotherapy compounds and small molecules in solid tumours. Dr Fandi has authored over 100 peer-reviewed publications, including first author publications in the Journal of Clinical Oncology. |